Highlights The Fund had several pockets of strength in September, including energy-related securities, a pharma company, and U.S.-based marijuana companies. Higher risk-free rates caused most bonds within the Fund to fall in price. We have become more constructive on longer duration issues due to a vastly improved risk/reward equation. The Pender Corporate Bond Fund returned […]